RSV admissions among infants fall sharply following vaccine rollout

Respiratory syncytial virus (RSV) infects thousands of infants annually, posing a significant health risk to newborns and young children who may develop severe breathing difficulties requiring hospital treatment. While the majority of cases result in mild symptoms, the potential for serious complications has led Denmark to implement a targeted preventive measure. Since the fall of 2025, pregnant women in the country have been offered an RSV vaccine designed to protect their infants during the vulnerable first months of life.

The vaccination program aims to reduce the incidence of severe RSV disease by transferring protective antibodies to the fetus, thereby shielding newborns before they are eligible for direct immunization. This initiative seeks to lower hospitalization rates and mitigate the impact of the virus among the youngest patients. The rollout represents a